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Editorial on the Research Topic
Deprescribing and Minimizing Use of Anticholinergic Medications
The global ageing population is increasingly challenged by multi-morbidity resulting in
polypharmacy (Soiza 2020). Over the last 2 decades, medications with anticholinergic properties
have been particularly strongly associated with a wide range of adverse outcomes (Lowry et al., 2011;
Stewart et al., 2021). Despite this, anticholinergic medications have a broad range of indications and
continue to be widely prescribed (Bostock et al., 2010). The present challenge is to consider how best
to minimize harm from this group of drugs. There is a growing evidence base for the safety and
efficacy of deprescribing approaches. However, deprescribing approaches to anticholinergic therapy
specifically remains relatively understudied. Although there are now multiple tools to measure the
extent of anticholinergic prescribing, it is unclear what tool performs best (Hanlon et al., 2020).
Moreover, there is currently no simple or reliable way for patients to know if their medications have
anticholinergic effects. There are significant evidence gaps around how best to optimize use of these
medications, how to usefully involve key stakeholders in decisions around their medications or what
deprescribing interventions should look like. The effects of deprescribing interventions on key
outcomes of patient safety and experience are unknown. Nevertheless, public and clinician awareness
of the dangers of anticholinergic therapy is growing and this is reflected in the increasing amounts of
research on anticholinergic medications and deprescribing opportunities. It is likely the next decade
will see major new research filling much of the evidence gap and significant improvements in the
safety of prescribing medications with anticholinergic effects. This special edition of Frontiers in
Pharmacology aimed to present the state of the art in responsibly prescribing and deprescribing
anticholinergic therapy.
A comprehensive systematic review and meta-analysis by (Graves-Morris et al.) found
anticholinergic burden is associated with an increased risk of death, odds ratio of around 1.4, in
those aged 65 or over. This is important because previous systematic reviews reported contrasting
results on the association between anticholinergic burden and mortality (Fox et al., 2014; Ruxton
et al., 2015). As well as including more recent studies, the present review focussed on studies
recruiting older people, in whom higher anticholinergic burden is more likely to lead to death due to
lower resilience. Interestingly, the association was present and of a similar magnitude even where
anticholinergic burden was “low.” The review included studies enrolling almost half a million people
and also sought to clarify if any particular measure of anticholinergic burden might be superior for
the purposes of risk prediction. It found a larger evidence base for the Anticholinergic Cognitive
Burden scale (ACB) (Boustani et al., 2008) but could not make recommendations on superiority of
any measure due to a lack of studies comparing various measures. This work further adds to the
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evidence for anticholinergics to cause serious harm, though it
should be noted the associationmay not be causal and the authors
found most studies had a high risk of bias, with high
heterogeneity in study design and reporting. Ultimately, only
randomised controlled trials of deprescribing or anticholinergic
avoidance strategies may prove that avoiding or minimising
anticholinergic use saves lives.
The challenges of designing such trials are neatly illustrated in
the study by (Cunningham et al.). Patients want to be engaged in
decisions around their medications, and interventions will need
to factor this in before they can even be trialled. Patients want to
be clear about the reasons for reducing their anticholinergic
burden to avoid misconceptions around the motivation for
reducing it. The importance of good communication was
manifested by their desire to have a point of contact
throughout the life of the trial, suggesting there are underlying
concerns about the safety of deprescribing approaches but also a
clear willingness to try out such approaches if any concerns can be
answered. Healthcare professionals were concerned about
workload and lines of responsibility. Pharmacists were felt to
be best placed to undertake reviews of anticholinergic burden, but
overall responsibility was felt best placed with GPs. This shows
the importance of a team approach and excellent communication
between GP, pharmacist and patient. Any intervention will need
to embed this team approach or be likely to be doomed to failure.
The better news was that willingness to participate in trials of
deprescribing interventions was high, perhaps reflecting
increasing awareness of the dangers of anticholinergic
prescribing and an acceptance that current practice may not
be in patients’ best interests.
The lack of clear consensus on how best to measure
anticholinergic burden is the focus of work by (Dihn et al.).
Their protocol for a study in the older general practice population
will investigate whether existing measures are able to predict falls
in this group. In the expectation that existing measures could be
improved upon, they will derive and validate a new measure of
anticholinergic burden specifically for the prediction of falls. It is
entirely credible that different anticholinergic burden scales may
perform better for predicting different outcome measures and
their precise calibration for prediction of clinically important
events is uncertain.
Most of the focus of anticholinergic burden quantification and
reduction has come from studies in North America, Europe and
Australasia. However, a reminder that this is a global
phenomenon comes from a new study by (Fadare et al.). They
found a third of older ambulatory patients in a tertiary referral
centre in Nigeria had routine exposure to anticholinergic
medications. As many as 15% had high levels of exposure.
Unsurprisingly, anticholinergic prescribing was associated with
polypharmacy and multi-morbidity suggesting these groups
could be the focus of any anticholinergic deprescribing
interventions.
Finally (Elliot et al.) remind us of the human story behind
concerns over anticholinergic prescribing. They present a case
report that neatly illustrates the dangers to patients, especially
where there is multi-morbidity, multiple healthcare providers and
cognitive impairment. This is a common combination that can
often lead to excessive anticholinergic prescribing and patient
harm. It also provides a timely reminder that many
anticholinergic medications are available as over-the-counter
medications without prescription, and these need to be
considered when measuring anticholinergic burden.
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